Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1995-7-6
pubmed:abstractText
Because the osteoporosis occurring in chronic cholestatic liver disease (CCLD) is associated with decreased bone formation and is reversible by liver transplantation, substances retained in plasma during cholestasis may impair osteoblast function. This hypothesis was tested using a new bioassay that measures plasma mitogenic activity (PMA) for normal human osteoblast-like (hOB) cells. In 29 jaundiced patients, mean PMA was 56.4% (P < 0.001) of that in 29 age- and sex-matched normal subjects, and the decrease in PMA was similar in the 14 with CCLD and the 15 with other causes of jaundice. Bile acids and bilirubin are the two major groups of products retained during cholestasis. The common conjugated bile acids and bilirubin were added to normal human plasma in concentrations simulating those found in patients with CCLD. Various bile salts had no effect on PMA whereas unconjugated bilirubin decreased PMA in a dose-dependent fashion (r = -0.98, P < 0.0001) without affecting cell viability. Relatively selective removal of bilirubin from the plasma by photobleaching normalized the decreased PMA in five jaundiced patients but produced no apparent change in five normal subjects. These data support the hypothesis that hyperbilirubinemia or possibly other photolabile substances impair osteoblast proliferative capacity and thus may play a major role in the pathogenesis of the osteoporosis associated with CCLD.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-1001976, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-13359653, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-13387703, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-14796348, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-1860683, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-1860685, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-1989266, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2220729, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2396503, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2474743, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2659986, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2783312, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2934760, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-2998572, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-330052, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-3388021, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-3780913, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-3804193, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-4062087, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-4324662, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-5064292, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-5168597, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-5880684, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-60515, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-6546800, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-7075948, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-7249880, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-7849563, http://linkedlifedata.com/resource/pubmed/commentcorrection/7769100-891628
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2581-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.
pubmed:affiliation
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.